TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06364904
Drug: Tislelizumab, Cisplatin, Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Chemoimmunotherapy:~1. Tislelizumab: 200mg, 1x time at d1 each cycle~2. Gemcitabine: 1000mg/ m2, in d1, d8 each cycle~3. Cisplatin: 70 mg/m2, in d2 each cycle~Tislelizumab maintenance therapy: after chemoimmunotherapy, 200mg, q3W.
Study: NCT05549661
Drug: Onvansertib
Normalized name: Onvansertib
DrugBank: Onvansertib (DB15110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT05562609
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ampoules and packaging for all arms will be identical in appearance.
Study: NCT05241873
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin will be administered intravenously (IV) on Day 1 of each cycle (every 3 weeks) for 4 to 6 cycles
Study: NCT05241873
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pemetrexed will be administered prior to carboplatin as an IV infusion on Day 1 of each cycle (every 3 weeks)
Study: NCT05009329
Drug: JAB-21822
Normalized name: JAB-21822
DrugBank: JAB-21822 (DB17478)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JAB-21822 will be administered orally
Study: NCT06525077
Drug: FT218
Normalized name: Solriamfetol
DrugBank: Solriamfetol (DB14754)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sodium oxybate for extended-release oral suspension
Study: NCT04865887
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 200mg, every 3 weeks, IV infusion
Study: NCT04865887
Drug: Lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 20 mg (2 capsules x10mg), daily, orally
Study: NCT06326411
Drug: NST-628
Normalized name: GLOVE NITRILE SM PFREE NSTERL TX
DrugBank: T-62 (DB12919)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NST-628 is a small molecule non-covalent pan-RAF/MEK dual molecular glue targeting RAF and MEK nodes of MAPK pathway.
Study: NCT06519617
Drug: Yi Qi Yang Yin Decoction
Normalized name: San Qi Root
DrugBank: Panax notoginseng root (DB14304)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Yi Qi Yang Yin Decoction (Dihuang 15g, Baihe 12g, Nanshashen 15g, celery Qinghao 10g, Malt 10g, Shengma 6g, Chaihu 6g) prescription for patients eligible for qi and yin deficiency was 200 ml twice daily for 12 weeks.
Study: NCT06519617
Drug: Hydroxychloroquine Sulfate
Normalized name: Hydroxychloroquine Sulfate
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine Sulfate Tablets 200-400mg daily for 12 weeks.
Study: NCT06058585
Drug: Finerenone
Normalized name: Finerenone
DrugBank: Finerenone (DB16165)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Finerenone 10mg or 20mg tablets, oral, once daily
Study: NCT06058585
Drug: Placebo Finerenone
Normalized name: Finerenone
DrugBank: Finerenone (DB16165)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Finerenone matched placebo tablets, oral, once daily
Study: NCT06197217
Drug: WPV01
Normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects in the WPV01 group will receive WPV01 600mg orally (200mg, 3 tablets per dose), 3 times daily (TID) for 15 consecutive treatments
Study: NCT05228184
Drug: Tirosint®-SOL
DrugBank: Rosin (DB11165)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage will be according to the USPI and Standard of Care.
Study: NCT05661708
Drug: Chitosan
Normalized name: Chitosan
DrugBank: Chitosan low molecular weight (20-200 mpa.s) (DB14155)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chitosan is a biodegradable, natural polyaminosaccharide with a nontoxic, non-allergenic, positively-charged polysaccharide derived from the deacetylation of chitin. Due to its molecular characteristics, chitosan has been used for improved hemostasis. Furthermore, chitosan has an antimicrobial and wound-healing effect
Study: NCT05283408
Drug: Dexmedetomidine infusion
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients received dexmedetomidine (0.5 µg/kg over 10 min before the induction of anesthesia), and then dexmedetomidine was infused at a rate of 0.4 μg/kg/h until 20 min before the end of operation
Study: NCT05283408
Drug: Co-administration dexmedetomidine and low-dose esketamine infusion
Normalized name: ethinyl estradiol
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients received a bolus infusion of dexmedetomidine (0.5 µg/kg) and esketamine (0.5 mg/kg)over 10 min before the induction of anesthesia, and then dexmedetomidine were infused at a rate of 0.4 µg/kg/h and 2 µg/kg/min until 20 min before the end of operation, respectively.
Study: NCT05283408
Drug: Co-administration dexmedetomidine and high-dose esketamine infusion
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients received a bolus infusion of dexmedetomidine (0.5 µg/kg) and esketamine (0.5 mg/kg)over 10 min before the induction of anesthesia, and then dexmedetomidine were infused at a rate of 0.4 µg/kg/h and 4 µg/kg/min until 20 min before the end of operation, respectively.
Study: NCT06675565
Drug: ALN-AGT01 RVR
Normalized name: ALN-AT3SC
DrugBank: Fitusiran (DB15002)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALN-AGT01 RVR will be administered subcutaneously (SC)
Study: NCT05434234
Drug: YL201
Normalized name: Lasmiditan
DrugBank: Lasmiditan (DB11732)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will be treated with YL201 intravenous (IV) infusion once every 3 weeks (Q3W) as a cycle.
Study: NCT05245877
Drug: enoxaparin/tinzaparin/dalteparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomized to the preoperative thromboprophylaxis will have their thromboprophylaxis initiated approximately 2-14 hours prior to the planned pancreatic surgery skin incision (depending on the center's current practice and logistics). Thromboprophylaxis can be initiated using enoxaparin (20 - 40 mg), tinzaparin (2500 - 4500 IU), or dalteparin (2500 - 5000 IU), with the dose based on patient's renal function according to the local standard of care. A center may reduce the dose 25-50% if the dose is given very close to the skin incision (i.e. at the morning of the operation instead of the evening before the operation).
Study: NCT05119140
Drug: Hydroxychloroquine
Normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400mg of hydroxychloroquine per oral daily
Study: NCT05119140
Drug: Mesalamine
Normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: the participant will maintain their current standard of care dose which can range from 1.5g to 4.8g of mesalamine per oral daily
Study: NCT05156268
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab will be administered intravenously (IV) at 200mg every 3 weeks.
Study: NCT05156268
Drug: Olaparib
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib will be administered orally at 300 mg every 12 hours.
Study: NCT06411860
Drug: Olpasiran
Normalized name: Olpasiran
DrugBank: Olpasiran (DB19001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a SC injection of olpasiran at dose level 1 or 2.
Study: NCT06411860
Drug: Moxifloxacin
Normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive a single dose of moxifloxacin as an oral tablet by mouth.
Study: NCT05323123
Drug: Pre-Exposure Prophylaxis (PrEP)
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDA-approved oral medication to reduce the risk of HIV infection
Study: NCT05642325
Drug: Vamikibart
Normalized name: Vamikibart
DrugBank: Vamikibart (DB18896)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive vamikibart IVT injection
Study: NCT06100874
Drug: Sacituzumab Govitecan
Normalized name: sacituzumab govitecan
DrugBank: Sacituzumab govitecan (DB12893)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Trop-2-directed antibody-drug conjugate, 180 mg single-dose glass vial, via intravenous infusion per protocol.
Study: NCT06100874
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Humanized IgG1 kappa monoclonal antibody, 150mg single-dose vial, via intravenous infusion per protocol.
Study: NCT06100874
Drug: Trastuzumab and Hyaluronidase-oysk
Normalized name: TRASTUZUMAB/HYALURONIDASE-OYSK
DrugBank: Hyaluronidase (ovine) (DB00070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant monoclonal antibody, 6 mL vial, via subcutaneous injection per protocol.
Study: NCT06544655
Drug: BMS-986484
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Specified dose on specified days
Study: NCT05652205
Drug: Linaclotide
Normalized name: Linaclotide
DrugBank: Linaclotide (DB08890)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capsule; oral
Study: NCT05652205
Drug: Placebo for Linaclotide
Normalized name: Linaclotide
DrugBank: Linaclotide (DB08890)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capsule; oral
Study: NCT06544291
Drug: CBD 300mg
Normalized name: CBD
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 3 Nantheia™ (100mg) softgel capsules and 3 placebo (0mg) softgel capsules will be administered to participants on one of the three test session days.
Study: NCT06544291
Drug: CBD 600mg
Normalized name: CBD
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 6 Nantheia™ (100mg) softgel capsules will be administered to participants on one of the three test session days.
Study: NCT05155033
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab 200 mg IV over approximately 30 minutes on Day 1 of cycles 1 and 2 during Courses 1 and 2.
Study: NCT05155033
Drug: Aldesleukin
Normalized name: Aldesleukin
DrugBank: Aldesleukin (DB00041)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aldesleukin (IL-2) administration \[600,000 IU/kg IV bolus every 8 hours continuing for up to 4 days (maximum 10 doses)\] starting on Day 1 of cycles 1 and 2 during Course 1.
Study: NCT04855656
Drug: RP-6306
Normalized name: RP-72
DrugBank: RP-72 (DB17156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral PKMYT1 Inhibitor
Study: NCT04855656
Drug: RP-3500
Normalized name: RP-72
DrugBank: RP-72 (DB17156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ATR Inhibitor
Study: NCT05879068
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV infusion
Study: NCT04900792
Drug: Ferumoxytol injection
Normalized name: ferumoxytol Injection
DrugBank: Ferumoxytol (DB06215)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ferumoxytol is an iron replacement product FDA approved for treatment of iron deficiency anemia in adult patients with chronic kidney disease (CKD). This trial uses the FDA approved dosage (512 mg iron) for iron-deficiency anemia in CKD.
Study: NCT04900792
Drug: Pharmacological ascorbate
Normalized name: ascorbate
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ascorbate
Study: NCT04900792
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide is a cytotoxic alkylating agent administered orally that penetrates well into the central nervous system. It is a standard-of-care treatment for GBM.
Study: NCT05102006
Drug: Toripalimab Injection
Normalized name: toripalimab Injection
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toripalimab is infused with a fixed dose of 3 mg/kg intravenously every three weeks
Study: NCT06202079
Drug: Insulin Degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin Degludec s.c., once-daily, treat-to-target dose
Study: NCT06271330
Drug: Faricimab
Normalized name: Faricimab
DrugBank: Faricimab (DB15303)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: switch from previous anti-VEGF agents to faricimab
Study: NCT05447286
Drug: NYX-783
Normalized name: NYX-2925
DrugBank: NYX-2925 (DB19149)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This study proposes to examine the safety, tolerability, and pharmacokinetics (PK) of NYX-783 at 50 mg and 150 mg doses versus Placebo (PBO) in combination with acute Oxycodone 15 mg and 30 mg in an inpatient randomized, cross-over study over 6 experimental sessions.
Study: NCT05447286
Drug: Oxycodone
Normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: This study proposes to examine the safety, tolerability, and pharmacokinetics (PK) of NYX-783 at 50 mg and 150 mg doses versus Placebo (PBO) in combination with acute Oxycodone 15 mg and 30 mg in an inpatient randomized, cross-over study over 6 experimental sessions.
Study: NCT06253715
Drug: Isoniazid
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once daily weight-based dose
Study: NCT06253715
Drug: Rifampin
Normalized name: Rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily weight-based dose
Study: NCT06253715
Drug: Pyrazinamide
Normalized name: Pyrazinamide
DrugBank: Pyrazinamide (DB00339)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once daily weight-based dose
Study: NCT06253715
Drug: Ethambutol
Normalized name: Ethambutol
DrugBank: Ethambutol (DB00330)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once daily weight-based dose
Study: NCT06253715
Drug: Rifapentine
Normalized name: Rifapentine
DrugBank: Rifapentine (DB01201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once daily weight-based dose
Study: NCT06253715
Drug: Moxifloxacin
Normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once daily weight-based dose
Study: NCT05864053
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketamine will be administered over a 45-minute period.
Study: NCT05864053
Drug: (2R,6R)-hydroxynorketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: (2R,6R)-Hydroxynorketamine hydrochloride will be administered over a 45-minute period.
Study: NCT05864053
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline will be administered over a 45-minute period.
Study: NCT05687136
Drug: Tuvusertib
Normalized name: Tuvusertib
DrugBank: Tuvusertib (DB18790)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT06023043
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Three (3) post operative intravenous dexamethasone injections at 8-hour intervals post-operatively. Dosing will be determined as 0.15 mg/kg per dose (WS)
Study: NCT05335941
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given by vein (IV)
Study: NCT05335941
Drug: Zimberelimab
Normalized name: Zimberelimab
DrugBank: Zimberelimab (DB17505)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given by vein (IV)
Study: NCT05335941
Drug: Etrumadenant
Normalized name: Etrumadenant
DrugBank: Etrumadenant (DB17506)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given by PO
Study: NCT05293717
Drug: Ruxolitinib
Normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.5% Ruxolitinib cream
Study: NCT06531512
Drug: Xianglei Tangzu Gao
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active ingredients: Extracts of Plectranthus amboinicus and Centella Asiatica
Study: NCT06532136
Drug: Deucravacitinib
Normalized name: Deucravacitinib
DrugBank: Deucravacitinib (DB16650)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deucravacitinib 6 mg orally once daily.
Study: NCT06216249
Drug: Lutetium Lu 177 Vipivotide Tetraxetan
Normalized name: lutetium Lu 177 vipivotide tetraxetan
DrugBank: Lutetium Lu-177 vipivotide tetraxetan (DB16778)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT05820711
Drug: MSC
Normalized name: adMSC
DrugBank: Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic Origins (DB15729)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of MSCs into submandibular glands at pre-specified dose level:~* Dose -1: 5 (4 - 6) x10\^6 MSCs (to be used only if Dose level 1 is not tolerated) per gland (0.5 ml)~* Dose 0: 10 (8 - 12) x10\^6 MSCs per gland (1 ml)~* Dose 1: 20 (16 - 24) x10\^6 MSCs per gland (2 ml)
Study: NCT05393024
Drug: Belantamab mafodotin
Normalized name: belantamab mafodotin
DrugBank: Belantamab mafodotin (DB15719)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: MMRR patients included in Named Patient Program e Expanded Access Program
Study: NCT06410248
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT06410248
Drug: Triapine
Normalized name: Triapine
DrugBank: Triapine (DB11940)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT05222906
Drug: Venglustat
Normalized name: Venglustat
DrugBank: Venglustat (DB14966)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet; oral
Study: NCT05222906
Drug: imiglucerase
Normalized name: Imiglucerase
DrugBank: Imiglucerase (DB00053)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: sterile lyophilized product; intravenous
Study: NCT05534984
Drug: Tecovirimat Oral Capsule
Normalized name: tecovirimat Oral Capsule
DrugBank: Tecovirimat (DB12020)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Drug: Tecovirimat Oral capsules~* Participants weighing 25 kg to less than 40 kg - Tecovirimat 400 mg every 12 hours for 14 days~* Participants weighing 40 kg to less than 120 kg - Tecovirimat 600 mg every 12 hours for 14 days~* Participants weighing 120 kg and over - Tecovirimat 600 mg every 8 hours for 14 days
Study: NCT05534984
Drug: Tecovirimat Oral Capsule (Open Label)
Normalized name: tecovirimat Oral Capsule
DrugBank: Tecovirimat (DB12020)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: * Participants weighing 4 to \<6kg and \>7 days old - Tecovirimat 50mg every 12 hours for 14 days~* Participants weighing 2.5 to \<4kg and \>7 days to \<4 weeks old - Tecovirimat 20 mg every 12 hours for 14 days~* Participants weighing 4 to \<6kg and ≤7 days old - Tecovirimat 50mg every 24 hours for 14 days~* Participants weighing 2.5 to \<4 kg and ≤7 days old - Tecovirimat 20mg every 24 hours for 14 days~* Participants weighing 6 kg to less than 13 kg - Tecovirimat 100 mg every 12 hours for 14 days~* Participants weighing 13 kg to less than 25 kg - Tecovirimat 200 mg every 12 hours for 14 days~* Participants weighing 25 kg to less than 40 kg - Tecovirimat 400 mg (2 capsules) every 12 hours for 14 days~* Participants weighing 40 kg to less than 120 kg - Tecovirimat 600 mg every 12 hours for 14 days~* Participants weighing 120 kg and over - Tecovirimat 600 mg every 8 hours for 14 days
Study: NCT06372496
Drug: Fluticasone furoate/umeclidinium bromide/vilanterol trifenatate
DrugBank: Clidinium (DB00771)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive FF/UMEC/VI
Study: NCT05836571
Drug: Cabozantinib
Normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT04192773
Drug: IV Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV lidocaine will be administered pre-fMRI and post-FMRI with each subject acting as their own control
Study: NCT06505759
Drug: Bromelain gel
DrugBank: Bromelains (DB13281)
Approvals — FDA: no, EMA: no, PMDA: no
Description: bromelain gel is prepared from bromelain capsules in laboratory
Study: NCT06505759
Drug: chlorhexidine gel
Normalized name: chlorhexidine Oral Gel
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: chlorhexidine gel is prepared from mouth wash
Study: NCT04960579
Drug: Rimiducid
Normalized name: Rimiducid
DrugBank: Rimiducid (DB04974)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safety switch activator
Study: NCT06444815
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: anti-pd1 antibody
Study: NCT05655949
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous infusion
Study: NCT05655949
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous infusion
Study: NCT05655949
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous infusion
Study: NCT05903092
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1500mg IV on Day 1 of every Cycle
Study: NCT05903092
Drug: Monalizumab
Normalized name: Monalizumab
DrugBank: Monalizumab (DB12824)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500mg IV on Day 1 of every Cycle
Study: NCT05903092
Drug: Carboplatin or Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: On Day 1 of Cycles 1-4 by IV:~Carboplatin: AUC 5-6 OR Cisplatin: 75-80mg/m\^2
Study: NCT05903092
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 80-100mg/m\^2 IV on Days 1-3 of Cycles 1-4
Study: NCT05908773
Drug: TTX-MC138-NODAGA-Cu64
Normalized name: TTX-MC138
DrugBank: TTX-MC138 (DB18628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TTX-MC138-NODAGA-Cu64 solution was developed as a PET radiopharmaceutical to permit assessment of delivery of TMX-MC138 to metastatic lesions in subjects with solid tumors. Subjects will be administered a microdose of TTX-MC138-NODAGA-Cu64 injection administered intravenously followed by whole body PET imaging.
Study: NCT05875493
Drug: JAB-21822
Normalized name: JAB-21822
DrugBank: JAB-21822 (DB17478)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 discrete single doses
Study: NCT04731272
Drug: Dulaglutide 0.75Mg/0.5Ml Inj Pen
Normalized name: DULAGLUTIDE 0.75MG/0.5ML INJ PEN
DrugBank: Dulaglutide (DB09045)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Randomized, open-label, cross-over study of 6 weeks exposure to dulaglutide 0.75 mg subcutaneous weekly or observation.